Work

Faculty Opinions recommendation of Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib.

Year: 2016

Type: peer-review

Source: Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature

DOI: 10.3410/f.725722564.793522191

Authors: Parameswaran Hari, Binod Dhakal

Institution: Medical College of Wisconsin

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4254081145

Cites:

Cited by:

Related to: 10